Advertisement
Advertisement
SRRK
Scholar Rock Holding Corporation Common Stock
49.35
USDSponsored
-1.93
-3.76%
May 15, 15:59 UTC -4
Closed
After-Market
49.34
-0.01
-0.01%
SRRK Earnings Reports
Positive Surprise Ratio
SRRK beat 15 of 32 last estimates.
47%
Next Report
Date of Next Report
Aug 04, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.85
Implied change from Q1 26 (Revenue/ EPS)
--
/+2.41%
Implied change from Q2 25 (Revenue/ EPS)
--
/-13.27%
Scholar Rock Holding Corporation Common Stock earnings per share and revenue
On May 07, 2026, SRRK reported earnings of -0.83 USD per share (EPS) for Q1 26, missing the estimate of -0.81 USD, resulting in a -1.62% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.40% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 12 analysts forecast an EPS of -0.85 USD, with revenue projected to reach -- USD, implying an increase of 2.41% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Satellos Bioscience Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.61
Actual
-$0.53
Surprise
+13.58%
Rani Therapeutics Holdings, Inc. Class A Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.04
Surprise
+12.85%
Citius Oncology, Inc. Common Stock
Report Date
May 15, 2026 For Q2 26
Estimate
-$0.01
Actual
-$1.43
Surprise
-13919.61%
MiNK Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.78
Actual
-$0.56
Surprise
+27.43%
Sensei Biotherapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.63
Actual
-$28.79
Surprise
-4452.50%
Neuphoria Therapeutics Inc. Common Stock
Report Date
May 15, 2026 For Q3 26
Estimate
-$0.98
Actual
-$0.09
Surprise
+90.90%
Lantern Pharma Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+18.30%
Cocrystal Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
BioCardia, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-24.78%
GT Biopharma Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.08
Actual
-$0.11
Surprise
-34.80%
FAQ
What were Scholar Rock Holding Corporation Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Scholar Rock Holding Corporation Common Stock reported EPS of -$0.83, missing estimates by -1.62%, and revenue of $0.00, 0% as expectations.
How did the market react to Scholar Rock Holding Corporation Common Stock's Q1 2026 earnings?
The stock price moved down -1.4%, changed from $47.11 before the earnings release to $46.45 the day after.
When is Scholar Rock Holding Corporation Common Stock expected to report next?
The next earning report is scheduled for Aug 04, 2026.
What are the forecasts for Scholar Rock Holding Corporation Common Stock's next earnings report?
Based on 12
analysts, Scholar Rock Holding Corporation Common Stock is expected to report EPS of -$0.85 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement